BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• 

  FDA

  Busy FDA gives rare disease sector complementary pathways, unanswered questions

  The FDA has expanded the regulatory toolkit during President Donald Trump’s second term, adding new mechanisms for rare diseases while putting the Biden-era platform technology designation into action.

  June 8, 2026

   · 

  8 min read

   · 

  Nick Paul Taylor
• 

  FDA

  Post-Makary, new rare disease framework faces fresh uncertainty

  As the FDA tries to clarify its intent for former FDA Commissioner Marty Makary’s plausible mechanism framework for bespoke therapies, experts emphasize the importance of expanding its scope to encompass rare diseases that affect more than just one or a few individuals.

  June 8, 2026

   · 

  7 min read

   · 

  Heather McKenzie
• Press Releases

  Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care

  June 8, 2026

   · 

  7 min read
• Press Releases

  Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

  June 8, 2026

   · 

  5 min read
• Press Releases

  People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

  June 8, 2026

   · 

  7 min read
• Press Releases

  New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis

  June 8, 2026

   · 

  8 min read
• Press Releases

  Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

  June 8, 2026

   · 

  11 min read
• Press Releases

  Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

  June 8, 2026

   · 

  13 min read
• Press Releases

  Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

  June 8, 2026

   · 

  7 min read
• Press Releases

  Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

  June 8, 2026

   · 

  25 min read